Table 2 Patients who filled the questionnaires: younger vs. older patients

N

86

23

-

Gender Male: Female

73:13

19:4

0.75

Age (years)^a

58 (51–64)

75 (72–80)

<0.0001

Histotype:^b

0.14

 Adenocarcinoma

62 (72.9)

13 (56.5)

 Squamous cell carcinoma

23 (27.1)

10 (43.5)

Tumour site:

0.42

 Cervical oesophagus

6 (7.0)

0

 Thoracic oesophagus

10 (11.6)

4 (17.4)

 Oesophago-gastric junction

70 (81.4)

19 (82.6)

Prognostic nutritional index^a

49.0 (46.5–52.0)

48.2 (44.4–50.7)

0.39

Charlson Comorbidity Index^a

2 (2–3)

3 (2–3)

0.09

Age related Charlson Comorbidity Index^ac

3 (2–4)

5 (5–6)

<0.0001

Neoadjuvant therapy

75 (87.2)

15 (65.2)

0.03

Type of neoadjuvant therapy:

-

 Chemotherapy

24 (32.0)

5 (33.3)

 Radiotherapy

1 (1.3)

0

 Chemo-radiotherapy

50 (66.7)

10 (66.7)

Hospital stay (days)^a

19 (16–24)

23 (18–30)

0.04

Pathological stage^d

0.07

 0

23 (26.7)

2 (8.7)

 I

16 (18.6)

4 (13.0)

 II

14 (16.3)

10 (43.5)

 III

29 (33.7)

7 (30.4)

 IV

4 (4.7)

1 (4.4)

Post-operative morbidity

20 (23.3)

9 (39.1)

0.18